july, 2014

29jul8:00 am10:00 amSingle-Asset vs. Platform Deals: Optionality & Value Considerations


Event Details

One question that many biotechs ask when it comes time to partner is:  How does one choose between having a monogamous relationship with one partner on a broad platform vs. doing single-asset deals with multiple partners?

Come join us to hear our panel of local BD experts who will weigh on this topic from both a pharma and venture capital perspective, and discuss various deals that span the spectrum, including:

  • The platform deal between Agios and Celgene,
  • The staged relationship between Alnylam and Genzyme
  • The long engagement between Isis and Biogen
  • The R&D externalization model exemplified by the Arteaus and Eli Lilly as part of the Atlas Venture Development Corp initiative.

This is a must-attend event for all BD professionals!


(Tuesday) 8:00 am - 10:00 am